CN102010901B

CN102010901B - Liquid phase chip and specific primer to test apo E gene and single nucleotide polymorphism (SNP) of 9p21 segment of chromosome

Info

Publication number: CN102010901B
Application number: CN 201010196862
Authority: CN
Inventors: 许嘉森; 秦会娟; 余刚; 曾涛
Original assignee: Guangzhou Surexam Bio Tech Co Ltd
Current assignee: Surexam Bio Tech Co Ltd
Priority date: 2010-06-08
Filing date: 2010-06-08
Publication date: 2013-08-28
Anticipated expiration: 2030-06-08
Also published as: CN102010901A

Abstract

The invention discloses a specific primer and a liquid phase chip to test apo E gene and single nucleotide polymorphism (SNP) of the 9p21 segment of chromosome. The liquid phase chip mainly comprises a pair of allele specific primer extension (ASPE) primers. The specific primer has the SEQ ID No.17 and SEQ ID No.18 corresponding to the C609T SNP site, extension primers and / or SEQ ID No. 19 and SEQ ID No.20 corresponding to the T471C SNP site. The tag sequence is from SEQ ID No.1 to SEQ ID No.16. Micro particles which contain specific anti-tag sequence and have different color codes are respectively contained, and the anti-tap sequence is from SEQ ID No.33 to SEQ ID No.48. The invention also discloses a liquid phase chip to test the apo E gene and the SNP of the 9p21 segment of chromosome. The test result of the liquid phase chip fully matches that of a sequencing method. The prepared liquid phase chip to test the apo-E gene and the SNP of the 9p21 segment of chromosome has high signal to noise ratio.

Description

Apo E gene and karyomit(e) 9p21 section SNP detect liquid-phase chip and Auele Specific Primer

Technical field

The invention belongs to biology field, relate to medical science and biotechnology, concrete relate to a kind of apo E gene and liquid-phase chip and Auele Specific Primer are detected in karyomit(e) 9p21 section SNP site.

Background technology

Apo E (Apolipoprotein E, apo E) is one of lipophorin important in the blood plasma.Apo E mainly participates in transportation, storage and the drainage of lipid in, secretion synthetic at liver and the metabolic process, and effects such as repair tissue, anticoagulant, immunomodulatory are arranged.The gene of people apo E is positioned at No. 19 long-armed 13 districts 2 of karyomit(e) to be with on (19q132), and full length gene is 3.7kb, contains 4 exons and 3 introns, and its cDNA is long to be 1.163kb.Apo E amyloid protein precursor is made up of 317 amino acid, contains 18 amino acid signal peptides, and ripe Apo E albumen is made up of 299 amino acid.Apo E gene has three allelotrope, and namely ε 2, ε 3 and ε 4 constitute 6 kinds of different genotype: 3 kinds homozygous (ε 2/ ε 2, ε 3/ ε 3, ε 4/ ε 4) and three kinds of heterozygous (ε 3/ ε 4, ε 2/ ε 3, ε 2/ ε 4) altogether.Its gene occurrence frequency there are differences because of different races and area, and in general crowd, ε 2 accounts for 8%, ε 3 and accounts for 78%, ε 4 and account for 14%.Because the 112nd polymorphism difference with the corresponding Nucleotide of 158 amino acids on the coding apo E peptide chain, three kinds of different isomer proteins are transcribed, translated into to three kinds of different allelotrope, be that amino acid on the 112nd and 158 of apo E ε 3 peptide chains is respectively halfcystine (Cys) and arginine (Arg), replaced by Cys and apo E ε 2 is Arg on the 158th, 4 Cys on the 112nd of apo E ε are replaced by Arg.Discover, different genotype crowd's risk of cardiovascular diseases increases according to ε 2＜ε 3＜ε 4 order, the carrier of ε 2/ ε 2 tends to take place the hyperlipidemia of III type, the raising of the rising of cholesterol levels and the coronary heart disease risk that causes thus is relevant in ε 4 allelotrope and the blood plasma, and apo E genotype plays an important role in the results for the treatment of to the patient such as the relevant environmental factors of prediction heart trouble, this statin treatment, dietetic treatment.

WTCCC suffered from coronary heart disease/myocardial infarction in 2007 to 1926 examples or serious family history person arranged and 2938 contrast experimenters' full genome association study result shows: (G＞C) is positioned at 9p21 zone (P=1.80 * 10-14) with the pleomorphism site rs1333049 of coronary heart disease dependency maximum.This result of study is verified in the crowd of East Asia in warp in 2008.2009 are confirmed in Chinese population.The same confirmation of PROVEIT-TIMI 22 researchs: rs1333049C allelotrope carrier uses his spit of fland intensive cure and benefits more than his spit of fland conventional treatment.Simultaneously, the pleomorphism site relevant with coronary heart disease also has A22086055G (rs10757274), A22114477G (rs10757278), A22105026G (rs2383206), A22105959G (rs2383207) and A22088619G (rs2891168), these 5 sites all with rs1333049 (G22115503C) complete linkage.

Domestic and international detection about risk of cardiovascular diseases at present day by day increases, the existing launch that detects apo E gene pleiomorphism, testing product as Celera company, Shanghai Zhujian Biological Engineering Co., Ltd, the fluorescence quantitative PCR method of the general PCR-based technology of present product, RFLP method and dna sequencing method etc., exist sensitivity low, the shortcoming that sample easily pollutes, false positive rate is high owing to detect the limitation of flux, can not satisfy the needs of practical application simultaneously.And karyomit(e) 9p21 section SNP site does not almost have relevant testing product at present both at home and abroad.

Summary of the invention

One of purpose of the present invention provides apo E gene SNP detection liquid-phase chip, and this liquid-phase chip can be used for detecting wild-type and the mutant of apo E two kinds of common genotype C609T of gene (rs7412) and T471C (rs429358).

The technical scheme that realizes above-mentioned purpose is as follows:

A kind of apo E gene SNP detection liquid-phase chip mainly includes:

(A) right at the ASPE primer of the wild-type of the SNP site of apo E gene design and mutant respectively, every ASPE primer is made up of at the Auele Specific Primer in SNP site tag sequence and the 3 ' end of 5 ' end, and described Auele Specific Primer is: at the SEQ ID NO.17 of C609T SNP and SEQ ID NO.18 and/or at SEQ ID NO.19 and the SEQ ID NO.20 of T471C SNP; Described tag sequence is selected from SEQ ID NO.1～SEQ ID NO.16;

(B) be coated with microballoon special anti-tag sequence, that have the different colours coding respectively, described anti-tag sequence is selected from the sequence among SEQID NO.33～SEQ ID NO.48, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing, and described anti-tag sequence also is provided with the spacerarm sequence in the middle of being connected with microballoon;

(C) be used for the amplimer that amplification has the apo E gene target sequence in C609T and/or T471C SNP site.

Preferably, described amplimer is SEQ ID NO.49～SEQ ID NO.50.

Preferably, described ASPE primer is to being the sequence of being made up of SEQ ID NO.1 and SEQ IDNO.17 at apo E gene C 609T SNP, the sequence of being made up of SEQ ID NO.2 and SEQ ID NO.18, and/or the sequence of forming at the sequence of being made up of SEQ ID NO.3 and SEQ ID NO.19 of apo E gene T471C, by SEQ ID NO.4 and SEQ ID NO.20.

Another object of the present invention provides the liquid-phase chip to apo E and karyomit(e) 9p21 section SNP synchronous detection.This liquid-phase chip can be used for detecting wild-type and the mutant of G22115503C (rs1333049), A22086055G (rs10757274), A22114477G (rs10757278), A22105026G (rs2383206), A22105959G (rs2383207) and A22088619G (rs2891168) sudden change of the wild-type of two kinds of common genotype C609T of apo E gene (rs7412) and T471C (rs429358) and mutant and chromosome segment 9p21.

The technical scheme that realizes above-mentioned purpose is as follows:

The liquid-phase chip that a kind of apo E gene and karyomit(e) 9p21 section SNP detect mainly includes:

(A) the ASPE primer of the wild-type that designs respectively at the SNP site of every kind of gene and mutant is right, every the ASPE primer is made up of at the Auele Specific Primer in goal gene SNP site tag sequence and the 3 ' end of 5 ' end, and described tag sequence is selected from SEQID NO.1～SEQ ID NO.16;

Described Auele Specific Primer is: at the SEQ ID NO.17 of apo E gene C 609TSNP and SEQ ID NO.18 and/or at SEQ ID NO.19 and the SEQ ID NO.20 of apo E gene T471C; And

At the SEQ ID NO.21 of karyomit(e) 9p21 section G22115503C SNP and SEQ ID NO.23 and the SEQ ID NO.25 of SEQ ID NO.24, A22114477G SNP and SEQ ID NO.27 and the SEQ ID NO.29 of SEQ ID NO.28, A22105959G SNP and SEQ ID NO.31 and the SEQ ID NO.32 of SEQ ID NO.30 and/or A22088619G SNP of SEQ ID NO.26, A22105026G SNP of SEQ ID NO.22, A22086055G SNP;

(C) amplimer of the target sequence of G22115503C, A22086055G, A22114477G, A22105026G, A22105959G and/or the A22088619G of the C609T that has apo E gene for increasing and T471C SNP and chromosome segment 9p21.

Preferably, described amplimer is: at SEQ ID NO.49 and the SEQ ID NO.50 of apo E gene; And at SEQ ID NO.51 and SEQ ID NO.52, SEQ ID NO.53 and SEQ ID NO.54, SEQ IDNO.55 and SEQ ID NO.56, SEQ ID NO.57 and SEQ ID NO.58, SEQ ID NO.59 and SEQ ID NO.60 and/or SEQ ID NO.61 and the SEQ ID NO.62 of chromosome segment 9p21.

Further, described ASPE primer is to being: and the sequence of forming at the sequence of being made up of SEQ ID NO.1 and SEQIDNO.17 of apo E gene C 609T SNP, by SEQ IDNO.2 and SEQ IDNO.18, and/or the sequence of forming at the sequence of being made up of SEQ ID NO.3 and SEQ ID NO.19 of apo E gene T471C SNP, by SEQ ID NO.4 and SEQ ID NO.20; And at the sequence of being formed by SEQ ID NO.5 and SEQ ID NO.21 of karyomit(e) 9p21 section and the sequence of being formed by SEQ ID NO.6 and SEQ ID NO.22, the sequence of being formed by SEQ ID NO.7 and SEQ ID NO.23 and the sequence of being formed by SEQ ID NO.8 and SEQ ID NO.24, the sequence of being formed by SEQ ID NO.9 and SEQ ID NO.25 and the sequence of being formed by SEQ ID NO.10 and SEQ ID NO.26, the sequence of being formed by SEQ ID NO.11 and SEQ ID NO.27 and the sequence of being formed by SEQ ID NO.12 and SEQ ID NO.28, the sequence of being formed by SEQ ID NO.13 and SEQ ID NO.29 and the sequence of being formed by SEQ ID NO.14 and SEQ ID NO.30, and/or the sequence of being formed by SEQ ID NO.15 and SEQ ID NO.31 and the sequence of being formed by SEQ ID NO.16 and SEQ IDNO.32.

Preferably, spacerarm sequence described in above-mentioned all liquid-phase chips is 5-10 T.

Major advantage of the present invention is:

1. the detected result of liquid-phase chip provided by the present invention and sequencing is coincide rate up to 100%.Prepared apo E gene and karyomit(e) 9p21 section SNP detect liquid-phase chip and have extraordinary signal-noise ratio, and there is not cross reaction between designed probe and the anti-tag sequence basically, choosing and tag sequence label and the specifically combination of ASPE primer of tag sequence label, anti-tag sequence label, can avoid cross reaction, realize the parallel detection in a plurality of SNP site.

2. the ASPE type specificity primer of the present invention's design has extraordinary specificity, can accurately distinguish the genotype of various types.

The 3 needed times of detection method of using liquid-phase chip of the present invention, realistic especially application needed well below sequencing technologies commonly used.

It is not high that 4 the present invention have not only overcome traditional solid phase chip susceptibility, and the defective of the repeatability difference of detected result is improved existing liquid-phase chip technology simultaneously, makes prepared microballoon can be applicable to different test items, has very strong expansion.The fluorescent signal value that detects improves greatly, thereby makes the sensitivity that detects be further enhanced, and signal to noise ratio strengthens, and detected result more accurately and reliably.

5. the detection method step of liquid-phase chip of the present invention is simple, and eight kinds of SNPs detect and can finish eight amplifications that contain the target sequence in SNP site by a step multiplex PCR, many uncertain factors of existing in the complex operations processes such as repeated multiple times PCR have been avoided, thereby can improve the detection accuracy rate greatly, embodied qualitative, quantitative analysis feature of accurate while.

Embodiment

Embodiment 1 apo E gene and karyomit(e) 9p21 section SNP detect liquid-phase chip, mainly include:

One, ASPE primer

(ε 2 at two kinds of common SNP site C609T of apo E, rs7412) and T471C (ε 4, rs429358) and the SNP site G22115503C (rs1333049) of karyomit(e) 9p21 section, A22086055G (rs10757274), A22114477G (rs10757278), A22105026G (rs2383206), A22105959G (rs2383207) and A22088619G (rs2891168), design specific primer sequence respectively.The ASPE primer is made up of " Tag sequence+specific primer sequence ".The ASPE primer sequence is as shown in the table:

Table 1 ASPE primer sequence (Tag sequence+specific primer sequence)

Every the ASPE primer comprises two parts, and 5 ' end is the specificity tag sequence at anti-tag sequence on the corresponding microballoon, and 3 ' end is mutant or the special primer fragment (shown in above-mentioned table 1) of wild-type.All ASPE primers are synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Every primer after synthetic is mixed with the stock solution of 100pmol/mL respectively with 10mmol/L Tris Buffer.

Two, the microballoon of anti-tag sequence bag quilt

According to designed ASPE Auele Specific Primer fragment, select the tag sequence, reduce between the anti-tag sequence of each microballoon to greatest extent and secondary structure that tag and ASPE Auele Specific Primer fragment may form, corresponding anti-tag sequence is as shown in table 2 on 12 kinds of microballoons numberings of selection and the microballoon:

Corresponding anti-tag sequence on table 2 microballoon numbering and the microballoon

12 kinds of microballoons selecting are available from U.S. Luminex company, with anti-tag sequence bag by on microballoon.Be connected with the spacerarm sequence of 5-10 T between anti-tag sequence and the microballoon, namely add the spacerarm sequence of the preceding paragraph 5-10 T before each anti-tag sequence, the anti-tag sequence is synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.With synthetic anti-tag sequence sterilization ddH ₂O is made into the stock solution of 100nmol/ml.Described spacerarm is for being used for anti-tag and microsphere surface is spaced apart or anti-tag is placed the sequence of hydrophilic environments.By the spacerarm sequence of suitable length is set between anti-tag sequence and microballoon, can reduce sterically hinderedly, improve the efficient of hybridization and the specificity of hybridization.Common spacerarm sequence comprises poly dT, i.e. poly (dT), and oligomerization four polyoxyethylene glycol and (CH2) n spacerarm (n 〉=3) are as (CH2) 12, (CH2) 18 etc.In addition, if exist poly (dA) to disturb, can also use poly (TTG) as spacerarm.Spacerarm of the present invention is preferably 5-10 T, and the process of microballoon bag quilt is as follows:

Get 5 * 10 respectively ⁶The carboxylated microballoon of individual above-mentioned numbering (available from Luminex company) is suspended in the MES solution of 50ul 0.1mol/L (pH4.5), adds the synthetic anti-tag molecule (100nmol/ml) of 10ul.EDC (N-(3-Dimethylaminopropyl-N-ethylcarbodiimide) (available from the Pierce Chemical company) working fluid of preparation 10ng/ml.Add the EDC working fluid of 2.5ul in the microballoon suspension, constant temperature was hatched 30 minutes, added the EDC working fluid of 2.5ul again, and constant temperature was hatched 30 minutes again.After reaction finished, the Tween-20 washing with 0.02% was once washed once with 0.1% SDS liquid again.The microballoon that is coated with the anti-tag sequence after the washing is resuspended in the Tris-EDTA solution [10mmol/L Tris (pH8.0)] of 100ul, and among the 1mmol/L EDTA, 2-8 ℃ keeps in Dark Place.

Three, amplify the primer of the target sequence that contains the mutational site

Two kinds of common SNP sudden change ε 2 and ε 4 of apo E gene, wherein, ε 2 all occurs on the apo E gene Exon 4 for the T471C sudden change for C609T sudden change, ε 4; And the G22115503C of karyomit(e) 9p21 section sudden change occurs in this section intergenic region.Utilize Primer5.0 design eight pairs of primers (seeing Table 3), amplify eight target sequences that contain the SNP site respectively.

Table 3 amplifies the primer of the target sequence with SNP site

All primers are synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Every primer after synthetic is mixed with the stock solution of 100pmol/mL respectively with 10mmol/LTrisBuffer.

In like manner, those skilled in the art according to the method described above, can independently make up apo E gene SNP detection liquid-phase chip according to actual needs.

Embodiment 2 uses apo E gene and karyomit(e) 9p21 section SNP to detect liquid-phase chip to the detection of sample

The prescription of described various solution is as follows:

MES damping fluid (pH5.0) prescription (250ml) of 50mM:

Reagent	The source	Final concentration	The consumption of every 250ml
				MES(2[N-Morpholino] ethanesulfonic acid)	Sigma M-2933	0.05M	2.44g
5M NaOH	Fisher SS256-500	---	5

2 * Tm hybridization buffer

Reagent	The source	Final concentration	The consumption of every 250ml
				1MTris-HCl，pH8.0	SigmaT3038	0.2M	50ml
5M NaCl	Sigma S5150	0.4M	20ml
				Triton X-100	Sigma T8787	0.16％	0.4ml

Be stored in 4 ℃ after the filtration.

The ExoSAP-IT test kit is available from U.S. USB company.

Biotin labeled dCTP is available from Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.

One, the DNA extraction of sample:

With reference to " molecular cloning " methods involving about DNA extraction, obtain DNA to be detected.

Two, the pcr amplification of testing sample

Utilize eight pairs of primers of Primer5.0 design, one step of multiplex PCR amplifies the exon 4 of apo E gene, with totally seven target sequences that contain the mutational site such as karyomit(e) 9p21 section intergenic region, the product size is respectively 264bp, 274bp, 269bp, 339bp, 225bp, 302bp and 269bp.Primer sequence (SEQ ID NO.49-62) is seen shown in the above-mentioned table 3.

At first prepare the multiple PCR primer working fluid: respectively get the primer stock solution 100ul of SEQ ID NO.49-62 respectively in the 1.5ml Eppendorf tube, mix and be the multiple PCR primer working fluid.The multi-PRC reaction system is as follows:

2 * damping fluid (contains Mg ²⁺) 25ul

DNTP (each 2.5mmol/L) 4ul

Taq enzyme (5U/ul) 0.2ul

Multiple PCR primer working fluid (each 8.3pmol/mL) 6ul

Template DNA (10ng/ul) 2ul

ddH ₂O 12.8ul

Be total to 50ul

The pcr amplification program is: 95 ℃ of 3min; 94 ℃ of 30s, 56 ℃ of 30s, 72 ℃ of 40s, 30 circulations; 72 ℃ of 10min; 4 ℃ of preservations are standby.

Three, the enzyme of PCR product is cut processing

1. get the reacted product of 7.5ul PCR, add 1ul 10 * SAP damping fluid, 1ul SAP enzyme and 0.5ul Exo-I enzyme;

2.37 ℃ hatch 15min, hatch 15min for 80 ℃, the enzyme that deactivation is unnecessary.The product that enzyme is cut after the processing is directly used in follow-up ASPE primer extension reaction.

Four, site-specific primer extension reaction (ASPE)

Utilize the ASPE primer of above-mentioned design to carry out primer extension reaction, in reaction process, mix biotin labeled dCTP, thereby make a plurality of biotin labeling on the reacted product band.

At first prepare the ASPE primer working fluid that mixes: get the corresponding wild-type with the 9p21 gene polymorphism sites of apo E to be detected and mutant ASPE primer stock solution 10ul respectively in the 1.5ml Eppendorf tube, add 10mmol/LTris Buffer and mend to 200ul, mix and be ASPE mix primer working fluid.The system of ASPE reaction is as follows:

10 * damping fluid 2ul

MgCl ₂(50mmol/L) 0.5ul

Biotin-dCTP(400umol/L) 0.25ul

DATP, dGTP, dTTP mixed solution (each 100umol/L) 1ul

Tsp enzyme (5U/ul) 0.25ul

ASPE primer working fluid (each 500nmol/L) 1ul that mixes

Enzyme is cut the pcr amplification product 5ul of processing

ddH ₂O 10ul

Be total to 20ul

Response procedures is: 96 ℃ of 2min; 94 ℃ of 30s, 54 ℃ of 1min, 72 ℃ of 2min, 30 circulations; 4 ℃ of preservations are standby.

Five, hybridization

1. according to the ASPE primer of design, (microballoon concentration is 2.5 * 10 to the corresponding optimum microballoon of every group selection ⁵Individual/ml);

2. get the microballoon of every kind of numbering of 1ul respectively in the Eppendorf tube of 1.5ml;

3. microballoon is in 〉=centrifugal the 1-2min of 10000g;

4. supernatant discarded, microballoon is resuspended in 2 * Tm hybridization buffer of 100ul, the vortex mixing;

5. get the above-mentioned microballoon suspension of 25ul in the corresponding hole of 96 hole filter plates, control wells adds the ddH of 25ul ₂O;

6. get the ASPE reaction solution of 5-25ul in corresponding hole, use ddH ₂O complements to 50ul;

7. encase 96 orifice plates with lucifuge with masking foil, 95 ℃ of 60s, 37 ℃ of 15min are hatched hybridization;

8. the microballoon after the hybridization is in 〉=centrifugal the 2-5min of 3000g;

9. remove supernatant, microballoon is resuspended in 1 * Tm hybridization buffer of 75ul;

10. microballoon is in 〉=centrifugal the 2-5min of 3000g;

11. microballoon is resuspended in 1 * Tm hybridization buffer of 75ul, adding 15ul concentration is Streptavidin-phycoerythrin (SA-PE) of 10ug/ml;

12.37 ℃ hatch 15min, on the Luminex instrument, detect.

Six, the result detects and data analysis

The reaction after product detects by Luminex serial analysis instrument.Detected result is shown in table 4～table 8.

Fluorescent value (MFI) and data processing there are following requirement:

1. each site need have an allelotrope MFI at least greater than 300 and greater than 10 * PCR negative control MFI;

2.NET MFI=sample MFI-PCR negative control MFI (NET MFI less than 0 with 0 the expression);

3. satisfy the data of above two conditions, calculate sudden change ratio by following formula:

Sudden change ratio=mutant NET MFI ÷ (mutant NET MFI+ wild-type NET MFI)

4. rule of thumb the sudden change ratio of each detection site is determined threshold value (cut-off value), to divide wild-type homozygote, heterozygote and mutant homozygote.

Use present method to detect 20 increments apo E and karyomit(e) 9p21 section polymorphism originally, experimental data meets above-mentioned requirements, therefore can calculate their sudden change ratio.Arranging of threshold value (cut-off value) is as follows: the sudden change ratio range is considered as the wild-type homozygote at 0%-20%; 30%-70% is considered as heterozygote; 80%-100% is considered as the anomaly homozygote.Compare with the liquid-phase chip result with the sequencing detection, calculate the identical rate of classifying method detected result provided by the present invention.Present method detects this apo E and the identical rate of karyomit(e) 9p21 section genotype detection result and sequencing result of 20 increments and reaches 100%.As seen apo E provided by the present invention and karyomit(e) 9p21 section SNP detect the SNP type that liquid-phase chip can detect apo E and karyomit(e) 9p21 section exactly, and the result is reliable and stable.

Table 4 pattern detection result one (MFI)

Table 5 pattern detection result two (MFI)

Table 6 sample apo E and karyomit(e) 9p21 block mutation ratio (%)

Table 7 sample apo E and karyomit(e) 9p21 block mutation type analysis result one (detected result)

Table 8 sample apo E and karyomit(e) 9p21 block mutation type analysis result two (sequencing results)

The liquid-phase chip of the ASPE primer that embodiment 3 is different is to the detection in apo E and karyomit(e) 9p21 section SNP site

One, the design (selection of Tag sequence and Anti-Tag sequence) of liquid-phase chip preparation

G22115503C site mutation detection liquid-phase chip with apo E gene C 609T site and karyomit(e) 9p21 section is example, respectively at the wild-type of C609T and G22115503C and the specific primer sequence of mutant design ASPE primer 3 ' end, the Tag sequence of ASPE primer 5 ' end then is selected from SEQ ID NO.1-SEQ ID NO.16, accordingly, bag is selected from SEQ ID NO.33-SEQ ID NO.48 by the anti-tag sequence with corresponding tag sequence complementary pairing on microballoon.Specific design is shown in following table (table 9).Synthetic, the anti-tag sequence bag of ASPE primer is described like embodiment 1 and embodiment 2 by microballoon, amplimer, detection method.

The design of table 9 liquid-phase chip preparation

Two, sample detection

Adopt the liquid-phase chip of above-mentioned design preparation, by embodiment 2 described testing processes and method sample 21-40 is detected, detected result is as follows:

Table 10 pattern detection result and Polymorphism Analysis

Table 11 pattern detection result and Polymorphism Analysis

Other is at the liquid-phase chip in different SNP sites, and the ASPE primer uses different Tag sequences, and its result is still reliable and stable, and concrete data are omitted.

Embodiment 4 different interval arm liquid-phase chips detect apo E gene SNP

One, the design (selection of spacerarm) of liquid-phase chip preparation

Detection liquid-phase chip with apo E gene T471C site mutation is example, verifies the influence that different spacerarm liquid-phase chips detects apo E gene SNP.At the wild-type of T471C and the specific primer sequence of mutant design ASPE primer 3 ' end, the Tag sequence of ASPE primer 5 ' end then is respectively SEQ ID NO.3 and SEQ ID NO.4, accordingly, bag is respectively SEQ ID NO.35 and SEQ ID NO.36 by the anti-tag sequence with corresponding tag sequence complementary pairing on microballoon.Verify the influence that different spacerarm liquid-phase chips detects apo E gene SNP, wherein, different spacerarms is (CH2) 12 or 5-10 T, and specific design is shown in following table (table 12).Synthetic, the anti-tag sequence bag of ASPE primer is described like embodiment 1 and embodiment 2 by microballoon, amplimer, detection method.

The design of table 12 liquid-phase chip preparation

Two, sample detection

Adopt the liquid-phase chip of above-mentioned design preparation, by embodiment 2 described testing processes and method sample 41-60 is detected, detected result is as follows:

Table 13 pattern detection result and Polymorphism Analysis

The spacerarm of embodiment 4 is the liquid-phase chip of (CH2) 12, its detected result is reliable and stable, and (detected result of other spacerarm is also like this, concrete data are omitted), and the hybridization rate of the spacerarm of preferred 5-10 T and hybridization specificity all are better than the liquid-phase chip that spacerarm is (CH2) 12, and the spacerarm of a 5-10 of the present invention T all is better than other spacerarms.

More than be at the specifying of possible embodiments of the present invention, but this embodiment is not in order to limiting claim of the present invention, does not allly break away from the equivalence that skill spirit of the present invention does and implement or change, all should be contained in the claim of the present invention.

Sequence table

＜110〉Guangzhou Yishan Biotechnology Co., Ltd.

＜120〉apo E gene and karyomit(e) 9p21 section SNP detect liquid-phase chip and Auele Specific Primer

<160>62

<170>PatentIn version 3.1

<210>1

<211>24

<212>DNA

＜213〉artificial sequence

<400>1

cttttcaatt acttcaaatc ttca 24

<210>2

<211>24

<212>DNA

＜213〉artificial sequence

<400>2

aatcaatctt cattcaaatc atca 24

<210>3

<211>24

<212>DNA

＜213〉artificial sequence

<400>3

tcaatcaatt acttactcaa atac 24

<210>4

<211>24

<212>DNA

＜213〉artificial sequence

<400>4

tcaattacct tttcaataca atac 24

<210>5

<211>24

<212>DNA

＜213〉artificial sequence

<400>5

taattataca tctcatcttc taca 24

<210>6

<211>24

<212>DNA

＜213〉artificial sequence

<400>6

aatcatacct ttcaatcttt taca 24

<210>7

<211>24

<212>DNA

＜213〉artificial sequence

<400>7

cttttacaat acttcaatac aatc 24

<210>8

<211>24

<212>DNA

＜213〉artificial sequence

<400>8

ttactcaaaa tctacacttt ttca 24

<210>9

<211>24

<212>DNA

＜213〉artificial sequence

<400>9

cttttcaaat caatactcaa cttt 24

<210>10

<211>24

<212>DNA

＜213〉artificial sequence

<400>10

tcaattactt cactttaatc cttt 24

<210>11

<211>24

<212>DNA

＜213〉artificial sequence

<400>11

caattcattt cattcacaat caat 24

<210>12

<211>24

<212>DNA

＜213〉artificial sequence

<400>12

tcaatcatta cacttttcaa caat 24

<210>13

<211>24

<212>DNA

＜213〉artificial sequence

<400>13

tcaatcatct ttatacttca caat 24

<210>14

<211>24

<212>DNA

＜213〉artificial sequence

<400>14

caatttactc atatacatca cttt 24

<210>15

<211>24

<212>DNA

＜213〉artificial sequence

<400>15

cttttcatca ataatcttac cttt 24

<210>16

<211>24

<212>DNA

＜213〉artificial sequence

<400>16

aatctacaaa tccaataatc tcat 24

<210>17

<211>17

<212>DNA

＜213〉artificial sequence

<400>17

ggacatggag gacgtgc 17

<210>18

<211>17

<212>DNA

＜213〉artificial sequence

<400>18

ggacatggag gacgtgt 17

<210>19

<211>18

<212>DNA

＜213〉artificial sequence

<400>19

ccgatgacct gcagaagt 18

<210>20

<211>18

<212>DNA

＜213〉artificial sequence

<400>20

ccgatgacct gcagaagc 18

<210>21

<211>21

<212>DNA

＜213〉artificial sequence

<400>21

taaccatatg atcaacagtt g 21

<210>22

<211>21

<212>DNA

＜213〉artificial sequence

<400>22

taaccatatg atcaacagtt c 21

<210>23

<211>22

<212>DNA

＜213〉artificial sequence

<400>23

tcaaatctaa gctgagtgtt ga 22

<210>24

<211>22

<212>DNA

＜213〉artificial sequence

<400>24

tcaaatctaa gctgagtgtt gg 22

<210>25

<211>19

<212>DNA

＜213〉artificial sequence

<400>25

ggtgtggtca ttccggtaa 19

<210>26

<211>19

<212>DNA

＜213〉artificial sequence

<400>26

ggtgtggtca ttccggtag 19

<210>27

<211>23

<212>DNA

＜213〉artificial sequence

<400>27

tccttagaaa tgttattgta gta 23

<210>28

<211>23

<212>DNA

＜213〉artificial sequence

<400>28

tccttagaaa tgttattgta gtg 23

<210>29

<211>19

<212>DNA

＜213〉artificial sequence

<400>29

tcctgttcgg atcccttca 19

<210>30

<211>19

<212>DNA

＜213〉artificial sequence

<400>30

tcctgttcgg atcccttcg 19

<210>31

<211>21

<212>DNA

＜213〉artificial sequence

<400>31

aaagatgtcc tgtttggaac a 21

<210>32

<211>21

<212>DNA

＜213〉artificial sequence

<400>32

aaagatgtcc tgtttggaac g 21

<210>33

<211>24

<212>DNA

＜213〉artificial sequence

<400>33

tgaagatttg aagtaattga aaag 24

<210>34

<211>24

<212>DNA

＜213〉artificial sequence

<400>34

tgatgatttg aatgaagatt gatt 24

<210>35

<211>24

<212>DNA

＜213〉artificial sequence

<400>35

gtattgtatt gaaaaggtaa ttga 24

<210>36

<211>24

<212>DNA

＜213〉artificial sequence

<400>36

gtatttgagt aagtaattga ttga 24

<210>37

<211>24

<212>DNA

＜213〉artificial sequence

<400>37

tgtagaagat gagatgtata atta 24

<210>38

<211>24

<212>DNA

＜213〉artificial sequence

<400>38

tgtaaaagat tgaaaggtat gatt 24

<210>39

<211>24

<212>DNA

＜213〉artificial sequence

<400>39

gattgtattg aagtattgta aaag 24

<210>40

<211>24

<212>DNA

＜213〉artificial sequence

<400>40

tgaaaaagtg tagattttga gtaa 24

<210>41

<211>24

<212>DNA

＜213〉artificial sequence

<400>41

aaagttgagt attgatttga aaag 24

<210>42

<211>24

<212>DNA

＜213〉artificial sequence

<400>42

aaaggattaa agtgaagtaa ttga 24

<210>43

<211>24

<212>DNA

＜213〉artificial sequence

<400>43

attgattgtg aatgaaatga attg 24

<210>44

<211>24

<212>DNA

＜213〉artificial sequence

<400>44

attgttgaaa agtgtaatga ttga 24

<210>45

<211>24

<212>DNA

＜213〉artificial sequence

<400>45

attgtgaagt ataaagatga ttga 24

<210>46

<211>24

<212>DNA

＜213〉artificial sequence

<400>46

aaagtgatgt atatgagtaa attg 24

<210>47

<211>24

<212>DNA

＜213〉artificial sequence

<400>47

aaaggtaaga ttattgatga aaag 24

<210>48

<211>24

<212>DNA

＜213〉artificial sequence

<400>48

atgagattat tggatttgta gatt 24

<210>49

<211>18

<212>DNA

＜213〉artificial sequence

<400>49

gcacggctgt ccaaggag 18

<210>50

<211>17

<212>DNA

＜213〉artificial sequence

<400>50

gcggatggcg ctgaggc 17

<210>51

<211>22

<212>DNA

＜213〉artificial sequence

<400>51

acacttctta ggctatcatt tc 22

<210>52

<211>21

<212>DNA

＜213〉artificial sequence

<400>52

acaaagggct cataattgct g 21

<210>53

<211>21

<212>DNA

＜213〉artificial sequence

<400>53

tgagcctatg tgtgtttctg c 21

<210>54

<211>21

<212>DNA

＜213〉artificial sequence

<400>54

taacttctgc ctcactctcc a 21

<210>55

<211>21

<212>DNA

＜213〉artificial sequence

<400>55

tggaaagtga caaagaggac a 21

<210>56

<211>19

<212>DNA

＜213〉artificial sequence

<400>56

tagactccac gctgttccc 19

<210>57

<211>20

<212>DNA

＜213〉artificial sequence

<400>57

ctatcctggt tgccccttct 20

<210>58

<211>20

<212>DNA

＜213〉artificial sequence

<400>58

aagccaccaa ggaagaggag 20

<210>59

<211>20

<212>DNA

＜213〉artificial sequence

<400>59

acttagccct tgggaccatt 20

<210>60

<211>21

<212>DNA

＜213〉artificial sequence

<400>60

tggggagtac agactacctt g 21

<210>61

<211>21

<212>DNA

＜213〉artificial sequence

<400>61

tagcacagga tgttccagtc a 21

<210>62

<211>21

<212>DNA

＜213〉artificial sequence

<400>62

agtaatggag gtgtggtcag c 21

Claims

1. an apo E gene SNP detection liquid-phase chip is characterized in that, mainly includes:

(C) be used for the amplimer that amplification has the apo E gene target sequence in C609T and/or T471C SNP site; Described amplimer is SEQ ID NO.49～SEQ ID NO.50.

2. apo E gene SNP detection liquid-phase chip according to claim 1, it is characterized in that described ASPE primer is to being the sequence of being made up of SEQ ID NO.1 and SEQ ID NO.17, and the sequence be made up of SEQ ID NO.2 and SEQ ID NO.18 at apo E gene C 609T SNP site; And/or at the sequence of being formed by SEQ ID NO.3 and SEQ IDNO.19 in apo E gene T471C SNP site, and the sequence formed by SEQ ID NO.4 and SEQ ID NO.20.

3. according to each described apo E gene SNP detection liquid-phase chip of claim 1-2, it is characterized in that described spacerarm is 5-10 T.

4. the liquid-phase chip that detects of an apo E gene and karyomit(e) 9p21 section SNP is characterized in that, mainly includes:

Described Auele Specific Primer is: at the SEQ ID NO.17 in apo E gene C 609T SNP site and SEQ ID NO.18 and/or at SEQ ID NO.19 and the SEQ ID NO.20 in apo E gene T471C SNP site; And at the SEQ ID NO.21 of karyomit(e) 9p21 section G22115503C SNP and SEQ ID NO.23 and the SEQ ID NO.25 of SEQ ID NO.24, A22114477G SNP and SEQ ID NO.27 and the SEQ ID NO.29 of SEQ ID NO.28, A22105959G SNP and SEQ ID NO.31 and the SEQ ID NO.32 of SEQ ID NO.30 and/or A22088619G SNP of SEQ ID NO.26, A22105026G SNP of SEQ ID NO.22, A22086055G SNP;

(C) amplimer of the target sequence of G22115503C, A22086055G, A 22114477G, A 22105026G, A 22105959G and/or the A22088619G of the C609T that has apo E gene for increasing and T471C SNP and chromosome segment 9p21; Described amplimer is: at SEQ ID NO.49 and the SEQ ID NO.50 of apo E gene; And at SEQ ID NO.51 and SEQ ID NO.52, SEQ ID NO.53 and SEQ ID NO.54, SEQ ID NO.55 and SEQ ID NO.56, SEQ ID NO.57 and SEQ ID NO.58, SEQ ID NO.59 and SEQ ID NO.60 and/or SEQID NO.61 and the SEQ ID NO.62 of chromosome segment 9p21.

5. the liquid-phase chip that detects of apo E gene according to claim 4 and karyomit(e) 9p21 section SNP, it is characterized in that, described ASPE primer is to being: the sequence of forming at the sequence of being made up of SEQ ID NO.1 and SEQ ID NO.17 in apo E gene C 609T SNP site, by SEQ ID NO.2 and SEQ ID NO.18, and/or the sequence of forming at the sequence of being made up of SEQ ID NO.3 and SEQ ID NO.19 in apo E gene T471C SNP site, by SEQ ID NO.4 and SEQ ID NO.20; And at the sequence of being formed by SEQ ID NO.5 and SEQ ID NO.21 of karyomit(e) 9p21 section and the sequence of being formed by SEQ IDNO.6 and SEQ ID NO.22, the sequence of being formed by SEQ ID NO.7 and SEQ ID NO.23 and the sequence of being formed by SEQ IDNO.8 and SEQ IDNO.24, the sequence of being formed by SEQ IDNO.9 and SEQ IDNO.25 and the sequence of being formed by SEQ IDNO.10 and SEQ ID NO.26, the sequence of being formed by SEQ ID NO.11 and SEQ ID NO.27 and the sequence of being formed by SEQID NO.12 and SEQ ID NO.28, the sequence of being formed by SEQ ID NO.13 and SEQ ID NO.29 and the sequence of being formed by SEQ ID NO.14 and SEQ ID NO.30, and/or the sequence of being formed by SEQ ID NO.15 and SEQ ID NO.31 and the sequence of being formed by SEQ ID NO.16 and SEQ ID NO.32.

6. according to the liquid-phase chip of each described apo E gene of claim 4-5 and karyomit(e) 9p21 section SNP detection, it is characterized in that described spacerarm is 5-10 T.

7. one kind is used for the Auele Specific Primer that apo E gene SNP detects, and it is characterized in that: its base sequence is: at the SEQ ID NO.17 of C609T SNP and SEQ ID NO.18 and/or at SEQ ID NO.19 and the SEQ ID NO.20 of T471C SNP.